Pembrolizumab,MK-4830,Belzutifan,Lenvatinib,Quavonlimab,Favezelimab
Eisai,Merck
['g plus', 'keymaker-u03b', 'lenvima', 'welireg', 'renal,(-adrenal)']
data from the phase 1/2 keymaker-u03b study showed promising results for the use of welireg plus lenvima to treat patients with clear cell renal cell carcinoma, #asco23 results showed. 
Cancer updates, research and education for patients with cancer, survivors and their caregivers to become empowered advocates in their journey.